ProMetic Life Sciences Inc. (TSE:PLI) Director Dwun-Hou Chen sold 108,566 shares of the company’s stock in a transaction on Friday, April 6th. The shares were sold at an average price of C$0.86, for a total transaction of C$93,366.76.
PLI stock opened at C$0.81 on Friday. ProMetic Life Sciences Inc. has a 1-year low of C$0.63 and a 1-year high of C$2.24.
Several research firms recently issued reports on PLI. National Bank Financial cut their price target on shares of ProMetic Life Sciences from C$1.00 to C$0.75 and set an “underperform” rating on the stock in a report on Wednesday, April 4th. Canaccord Genuity lowered their target price on shares of ProMetic Life Sciences from C$4.00 to C$2.00 in a research note on Tuesday, April 3rd. Royal Bank of Canada lowered their target price on shares of ProMetic Life Sciences from C$3.50 to C$2.00 and set an “outperform” rating for the company in a research note on Monday, April 2nd. CIBC lowered their target price on shares of ProMetic Life Sciences from C$2.15 to C$0.60 in a research note on Monday, April 2nd. Finally, TD Securities lowered their target price on shares of ProMetic Life Sciences from C$3.50 to C$2.00 in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. ProMetic Life Sciences has an average rating of “Buy” and an average target price of C$1.89.
ILLEGAL ACTIVITY WARNING: “Dwun-Hou Chen Sells 108,566 Shares of ProMetic Life Sciences Inc. (PLI) Stock” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://dakotafinancialnews.com/2018/04/13/dwun-hou-chen-sells-108566-shares-of-prometic-life-sciences-inc-pli-stock.html.
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.